Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Hepatitis C Virus NS3 Helicase Inhibitor Discovery

In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010.
[updated ].
Affiliations
Free Books & Documents
Review

Hepatitis C Virus NS3 Helicase Inhibitor Discovery

Kelin Li et al.
Free Books & Documents

Excerpt

The Hepatitis C virus (HCV) is a major cause of liver failure and hepatocellular carcinoma, with about 170 million people infected worldwide. Replication of HCV in human cells requires the action of the HCV non-structural protein 3 (NS3), which exhibits both protease and helicase activities. Since there are numerous NS3 protease inhibitors but few NS3 helicase inhibitors, the goal here was to develop specific NS3 helicase inhibitors. During assay development, we discovered that trace components in the dye mixtures thioflavine S and primuline were potent inhibitors of the NS3 helicase. Based on the common structure of these components we designed ML283. The probe candidate is a potent inhibitor of the NS3 helicase enzyme and can be synthesized in the necessary quantities for further investigation. ML283 is more potent and specific than other recently reported NS3 helicase inhibitors under the same assay conditions, allowing a direct comparison. Preliminary experiments indicate that this compound is able to penetrate cells and inhibit HCV replication with no significant cytotoxicity. Thus the probe would be a useful tool for the investigation of viral helicases.

PubMed Disclaimer

References

Resulting Publications

    1. Li K, Frankowski KJ, Belon CA, Neuenswander B, Ndjomou J, Hanson AM, Shanahan MA, Schoenen FJ, Blagg BSJ, Aubé J, Frick DN. Optimization of Potent Hepatitis C Virus NS3 Helicase Inhibitors Isolated from the Yellow Dyes Thioflavine S and Primuline. J. Med. Chem. 2012;55(7):3319–3330. - PMC - PubMed
    1. Mukherjee S, Hanson AM, Shadrick WR, Ndjomou J, Sweeney NL, Hernandez J, Bartczak D, Li K, Frankowski KJ, Heck JA, Arnold LA, Schoenen FJ, Frick DN. Identification and Analysis of Hepatitis C Virus NS3 Helicase Inhibitors Using Nucleic Acid Binding Assays. Nucleic Acids Res. 2012;40(17):8607–8621. - PMC - PubMed
    1. Ndjomou J, Kolli R, Mukherjee S, Shadrick WR, Hanson AM, Sweeney NL, Bartczak D, Li K, Frankowski KJ, Schoenen FJ, Frick DN. Fluorescent Primuline Derivatives Inhibit Hepatitis C Virus NS3-Catalyzed RNA Unwinding, Peptide Hydrolysis and Viral Replicase Formation. Antiviral Res. 2012;96(2):245–255. - PMC - PubMed
    1. Sweeney NL, Shadrick WR, Mukherjee S, Li K, Frankowski KJ, Schoenen FJ, Frick DN. Primuline Derivatives That Mimic RNA To Stimulate Hepatitis C Virus NS3 Helicase-Catalyzed ATP Hydrolysis. J. Biol. Chem. 2013 May 23; [Epub ahead of print] - PMC - PubMed

References

    1. Garber K. Hepatitis C: move over interferon. Nat Biotechnol. 2011;29:963–966. - PubMed
    1. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436:933–938. - PubMed
    1. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428. - PubMed
    1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217. - PMC - PubMed
    1. Lam AM, Frick DN. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol. 2006;80:404–411. - PMC - PubMed

Full SciFinder bibliography

    1. Cichero E, Basile A, Turco MC, Mazzei M, Fossa P. Scouting new molecular targets for CFTR therapy: the HSC70/BAG-1 complex. A computational study. Med. Chem. Res. 2012 doi: 10.1007/s00044-012-9985-1. - DOI
    1. Isono T, Omura N. Copper electroplating bath compositions and method for filling via holes and through holes by electroplating of copper. JP 2012021202 A 20120202 Jpn. Kokai Tokkyo Koho. 2012
    1. Md.Sheikh RK, Farouqui AN, Yahya R, Hassan A. Effect of acid modification on dyeing properties of Rajshahi silk fabric with different dye classes. Fibers and Polymers. 2011;12:642–647.
    1. Hariharasuthan R, Nageswara RA. Comparative studies of Sorel’s cement on selected dyes. Indian Journal of Science and Technology. 2011;4:410–413.
    1. Sharp A, Crabb SJ, Johnson PW, Hague A, Cutress R, Townsend PA, Ganesan A, Packham G. Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions. J Pharmacol Exp Ther. 2009;331:680–689. - PMC - PubMed

LinkOut - more resources